These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2213677)

  • 1. The clinical and scientific basis of drug toxicity. A report of a conference.
    Shah RR; Walley T
    J R Coll Physicians Lond; 1990 Jul; 24(3):219-23. PubMed ID: 2213677
    [No Abstract]   [Full Text] [Related]  

  • 2. Suspected adverse reactions, 2007.
    Dyer F; Spagnuolo-Weaver M; Coolees S; Tait A
    Vet Rec; 2008 Jul; 163(3):69-72. PubMed ID: 18702197
    [No Abstract]   [Full Text] [Related]  

  • 3. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.
    Bee JS; Goletz TJ; Ragheb JA
    J Pharm Sci; 2012 Oct; 101(10):3580-5. PubMed ID: 22736570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric registries at the Food and Drug Administration: design aspects that increase their likelihood of success.
    Winiecki SK; Tejero-Taldo MI; Avant D; Murphy D; McMahon AW
    Pharmacoepidemiol Drug Saf; 2016 May; 25(5):602-5. PubMed ID: 26687996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing safety of biologics and biological devices.
    Woo EJ
    Spine J; 2014 Mar; 14(3):560-5. PubMed ID: 24342704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Did the drug do it?
    Grob PR
    Br Med J (Clin Res Ed); 1986 Sep; 293(6549):757. PubMed ID: 3094642
    [No Abstract]   [Full Text] [Related]  

  • 8. Researching drug treatment.
    Martys CR
    Br Med J (Clin Res Ed); 1984 Nov; 289(6455):1353-4. PubMed ID: 6437549
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety issues specific to clinical development of protein therapeutics.
    Haller CA; Cosenza ME; Sullivan JT
    Clin Pharmacol Ther; 2008 Nov; 84(5):624-7. PubMed ID: 18701885
    [No Abstract]   [Full Text] [Related]  

  • 10. Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities.
    DiMartino LD; Curtis LH; Williams RL; Abernethy DR; Schulman KA
    Food Drug Law J; 2008; 63(4):891-900. PubMed ID: 19601387
    [No Abstract]   [Full Text] [Related]  

  • 11. Taking immunogenicity assessment of therapeutic proteins to the next level.
    Büttel IC; Chamberlain P; Chowers Y; Ehmann F; Greinacher A; Jefferis R; Kramer D; Kropshofer H; Lloyd P; Lubiniecki A; Krause R; Mire-Sluis A; Platts-Mills T; Ragheb JA; Reipert BM; Schellekens H; Seitz R; Stas P; Subramanyam M; Thorpe R; Trouvin JH; Weise M; Windisch J; Schneider CK
    Biologicals; 2011 Mar; 39(2):100-9. PubMed ID: 21353596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription drugs, products liability, and preemption of tort litigation.
    DeAngelis CD; Fontanarosa PB
    JAMA; 2008 Oct; 300(16):1939-41. PubMed ID: 18940985
    [No Abstract]   [Full Text] [Related]  

  • 13. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-related risks.
    Klotz U
    Eur J Clin Pharmacol; 2007 Nov; 63(11):983-4. PubMed ID: 17882407
    [No Abstract]   [Full Text] [Related]  

  • 15. Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules.
    Ebbers HC; Al-Temimi E; Moors EH; Mantel-Teeuwisse AK; Schellekens H; Leufkens HG
    BioDrugs; 2013 Apr; 27(2):167-74. PubMed ID: 23400874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of postmarketing drug surveillance.
    Smart AJ; Walters L
    S Afr Med J; 1992 Dec; 82(6):383-4. PubMed ID: 1465681
    [No Abstract]   [Full Text] [Related]  

  • 17. Why do doctors not report adverse drug reactions?
    Leiper JM; Lawson DH
    Neth J Med; 1985; 28(12):546-50. PubMed ID: 3911083
    [No Abstract]   [Full Text] [Related]  

  • 18. Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products.
    Marszal E; Fowler E
    J Pharm Sci; 2012 Oct; 101(10):3555-9. PubMed ID: 22736535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical usefulness of drug surveillance studies].
    Soto Alvarez J
    Aten Primaria; 1995 Oct; 16(7):455-6. PubMed ID: 7495957
    [No Abstract]   [Full Text] [Related]  

  • 20. Postmarketing surveillance for drug safety.
    Holden WL; Scarazzini LJ
    Clin Pharmacol Ther; 2004 Nov; 76(5):503; author reply 504-5. PubMed ID: 15536464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.